1. AB0511 International Consensus on ANCA Testing and Interpretation Beyond Systemic Vasculitis
- Author
-
Moiseev, S, Cohen Tervaert, J, Arimura, Y, Bogdanos, D, Elena, C, Damoiseaux, J, Ferrante, M, Flores-Suárez, L, Fritzler, M, Invernizzi, P, Jayne, D, Jennette, J, Little, M, Mcadoo, S, Novikov, P, Pusey, C, Radice, A, Salama, A, Savige, J, Segelmark, M, Shoenfeld, Y, Sinico, R, De Sousa, M, Specks, U, Terrier, B, Tzioufas, A, Vermeire, S, Zhao, M, Bossuyt, X, S Moiseev, JW Cohen Tervaert, Y Arimura, D Bogdanos, C Elena, J Damoiseaux, M Ferrante, LF Flores-Suárez, M Fritzler, P Invernizzi, D Jayne, JC Jennette, M Little, SP Mcadoo, P Novikov, CD Pusey, A Radice, AD Salama, J Savige, M Segelmark, Y Shoenfeld, RA Sinico, MJR De Sousa, U Specks, B Terrier, A Tzioufas, S Vermeire, MH Zhao, X Bossuyt, Moiseev, S, Cohen Tervaert, J, Arimura, Y, Bogdanos, D, Elena, C, Damoiseaux, J, Ferrante, M, Flores-Suárez, L, Fritzler, M, Invernizzi, P, Jayne, D, Jennette, J, Little, M, Mcadoo, S, Novikov, P, Pusey, C, Radice, A, Salama, A, Savige, J, Segelmark, M, Shoenfeld, Y, Sinico, R, De Sousa, M, Specks, U, Terrier, B, Tzioufas, A, Vermeire, S, Zhao, M, Bossuyt, X, S Moiseev, JW Cohen Tervaert, Y Arimura, D Bogdanos, C Elena, J Damoiseaux, M Ferrante, LF Flores-Suárez, M Fritzler, P Invernizzi, D Jayne, JC Jennette, M Little, SP Mcadoo, P Novikov, CD Pusey, A Radice, AD Salama, J Savige, M Segelmark, Y Shoenfeld, RA Sinico, MJR De Sousa, U Specks, B Terrier, A Tzioufas, S Vermeire, MH Zhao, and X Bossuyt
- Abstract
Background: ANCA can be detected in sera from patients with autoimmune, inflammatory, infectious or neoplastic diseases. Objectives: To issue a Consensus Statement on ANCA testing and interpretation beyond systemic vasculitis. Methods: This Statement was prepared by a group of experts, based on the results of a comprehensive search in PubMed. Results: In certain settings beyond systemic vasculitis, ANCA may have diagnostic, clinical, and/or prognostic relevance. Testing for PR3- and MPO-ANCA by specific immunoassays should be performed in any patient with clinical features suggesting ANCA-associated vasculitis and in patients with anti-GBM disease and idiopathic interstitial pneumonia. Routine ANCA testing is not recommended in patients with connective tissue diseases (CTD), autoimmune liver diseases, inflammatory bowel diseases, infections, and/or malignancy unless there is evidence for small vessel vasculitis. ANCA testing by specific immunoassays may be useful in patients with rheumatoid arthritis, systemic sclerosis or primary Sjögren’s syndrome who have kidney disease with a nephritic sediment or in patients with systemic lupus erythematosus if a kidney biopsy shows prominent necrotizing and crescentic lesions or proliferative lupus nephritis. ANCA testing may be justified in patients with suspected autoimmune hepatitis type 1, who do not have conventional disease-related autoantibodies, or in patients with inflammatory bowel diseases in case of diagnostic uncertainty to discriminate ulcerative colitis from Crohn’s disease. In these cases, ANCA should be tested by indirect immunofluorescence since target antigens are not well characterized. ANCA against bactericidal/permeability-increasing protein may be a biomarker for deteriorating lung function and a poor prognosis in patients with cystic fibrosis. Conclusion: ANCA testing is clinically relevant not only in patients with manifestations suggesting systemic vasculitis, but also in patients with certain other
- Published
- 2020